Patent · US Active

Vaccine against RSV

US11229694B2 · kind B2 · utility

9Cited by

29References

8Claims

0Family size

Assignee

Janssen Vaccines & Prevention B.V.

Inventors

Johannes Petrus Maria Langedijk · Amsterdam, NL
Dirk André Emmy Roymans · Turnhout, BE

Key dates

Filing date	Oct 1, 2019
Grant date	Jan 25, 2022
Priority date	—
Expiry date	Oct 1, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2760/18534
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compositions including a recombinant respiratory syncitial virus (RSV) Fusion (F) polypeptide that is stabilized in the pre-fusion conformation are described. The RSV F polypeptide includes at least one mutation as compared to a wild type RSV F polypeptide and the at least one mutation is a) a mutation of the amino acid aspartic acid (D) on position 486, b) a mutation of the amino acid aspartic acid (D) on position 489, or c) a mutation of the amino acid serine (S) on position 398 and/or the amino acid lysine (K) on position 394. Compositions including an isolated nucleic acid molecule encoding the stable RSV F polypeptides are also described.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.